These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29631964)

  • 1. Insights Into Hypertrophic Cardiomyopathy Evaluation Through Follow-up of a Founder Pathogenic Variant.
    Lorca R; Gómez J; Martín M; Cabanillas R; Calvo J; León V; Pascual I; Morís C; Coto E; R Reguero JJ
    Rev Esp Cardiol (Engl Ed); 2019 Feb; 72(2):138-144. PubMed ID: 29631964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain.
    Sabater-Molina M; Saura D; García-Molina Sáez E; González-Carrillo J; Polo L; Pérez-Sánchez I; Olmo MDC; Oliva-Sandoval MJ; Barriales-Villa R; Carbonell P; Pascual-Figal D; Gimeno JR
    Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):105-114. PubMed ID: 28029522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophic cardiomyopathy in myosin-binding protein C (
    Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
    Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
    Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
    J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males.
    Méndez I; Fernández AI; Espinosa MÁ; Cuenca S; Lorca R; Rodríguez JF; Tamargo M; García-Montero M; Gómez C; Vilches S; Vázquez N; Álvarez R; Medrano C; Yotti R; Fernández-Avilés F; Bermejo J
    Open Heart; 2021 Sep; 8(2):. PubMed ID: 34588271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy.
    Waldmüller S; Sakthivel S; Saadi AV; Selignow C; Rakesh PG; Golubenko M; Joseph PK; Padmakumar R; Richard P; Schwartz K; Tharakan JM; Rajamanickam C; Vosberg HP
    J Mol Cell Cardiol; 2003 Jun; 35(6):623-36. PubMed ID: 12788380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models.
    Hodatsu A; Konno T; Hayashi K; Funada A; Fujita T; Nagata Y; Fujino N; Kawashiri MA; Yamagishi M
    Am J Physiol Heart Circ Physiol; 2014 Dec; 307(11):H1594-604. PubMed ID: 25281569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene.
    Ehlermann P; Weichenhan D; Zehelein J; Steen H; Pribe R; Zeller R; Lehrke S; Zugck C; Ivandic BT; Katus HA
    BMC Med Genet; 2008 Oct; 9():95. PubMed ID: 18957093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers.
    Lorenzini M; Norrish G; Field E; Ochoa JP; Cicerchia M; Akhtar MM; Syrris P; Lopes LR; Kaski JP; Elliott PM
    J Am Coll Cardiol; 2020 Aug; 76(5):550-559. PubMed ID: 32731933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy.
    Erdmann J; Raible J; Maki-Abadi J; Hummel M; Hammann J; Wollnik B; Frantz E; Fleck E; Hetzer R; Regitz-Zagrosek V
    J Am Coll Cardiol; 2001 Aug; 38(2):322-30. PubMed ID: 11499719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening.
    Christiaans I; Birnie E; van Langen IM; van Spaendonck-Zwarts KY; van Tintelen JP; van den Berg MP; Atsma DE; Helderman-van den Enden AT; Pinto YM; Hermans-van Ast JF; Bonsel GJ; Wilde AA
    Eur Heart J; 2010 Apr; 31(7):842-8. PubMed ID: 20019025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and genetic diagnosis of familial hypertrophic cardiomyopathy: Results in pediatric cardiology.
    Cardoso B; Gomes I; Loureiro P; Trigo C; Ferreira Pinto F
    Rev Port Cardiol; 2017 Mar; 36(3):155-165. PubMed ID: 28214152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel phenotype-genotype correlations of hypertrophic cardiomyopathy caused by mutation in α-actin and myosin-binding protein genes in three unrelated Chinese families.
    Yang QL; Bian YY; Wang B; Zuo L; Zhou MY; Shao H; Zhang YM; Liu LW
    J Cardiol; 2019 May; 73(5):438-444. PubMed ID: 30600190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
    van Velzen HG; Schinkel AFL; Oldenburg RA; van Slegtenhorst MA; Frohn-Mulder IME; van der Velden J; Michels M
    Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28794111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic spectrum of the first Belgian
    Boen HM; Alaerts M; Van Laer L; Saenen JB; Goovaerts I; Bastianen J; Koopman P; Vanduynhoven P; De Vuyst E; Rosseel M; Heidbuchel H; Van Craenenbroeck EM; Loeys B
    Front Genet; 2024; 15():1392527. PubMed ID: 38836037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.
    Jääskeläinen P; Kuusisto J; Miettinen R; Kärkkäinen P; Kärkkäinen S; Heikkinen S; Peltola P; Pihlajamäki J; Vauhkonen I; Laakso M
    J Mol Med (Berl); 2002 Jul; 80(7):412-22. PubMed ID: 12110947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
    Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
    Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers.
    Michels M; Soliman OI; Phefferkorn J; Hoedemaekers YM; Kofflard MJ; Dooijes D; Majoor-Krakauer D; Ten Cate FJ
    Eur Heart J; 2009 Nov; 30(21):2593-8. PubMed ID: 19666645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myosin-binding Protein C Compound Heterozygous Variant Effect on the Phenotypic Expression of Hypertrophic Cardiomyopathy.
    Rafael JF; Cruz FEDS; Carvalho ACC; Gottlieb I; Cazelli JG; Siciliano AP; Dias GM
    Arq Bras Cardiol; 2017 Apr; 108(4):354-360. PubMed ID: 28538763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (β-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy.
    Weissler-Snir A; Hindieh W; Gruner C; Fourey D; Appelbaum E; Rowin E; Care M; Lesser JR; Haas TS; Udelson JE; Manning WJ; Olivotto I; Tomberli B; Maron BJ; Maron MS; Crean AM; Rakowski H; Chan RH
    Circ Cardiovasc Imaging; 2017 Feb; 10(2):. PubMed ID: 28193612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.